Beyond peptides and mAbs-current status and future perspectives for biotherapeutics with novel constructs
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond peptides and mAbs-current status and future perspectives for biotherapeutics with novel constructs
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 55, Issue S3, Pages S4-S20
Publisher
Wiley
Online
2015-02-24
DOI
10.1002/jcph.407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension
- (2014) Michie Toba et al. AMERICAN JOURNAL OF PATHOLOGY
- The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review
- (2014) Winnie Sohn et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A drug safety evaluation of rituximab and risk of hepatitis B
- (2014) Peter Riedell et al. Expert Opinion On Drug Safety
- Cell penetrating peptides: Efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules
- (2014) Samad Mussa Farkhani et al. PEPTIDES
- Romiplostim for management of chemotherapy-induced thrombocytopenia
- (2014) R. Parameswaran et al. SUPPORTIVE CARE IN CANCER
- Chemically programmed antibodies
- (2014) Christoph Rader TRENDS IN BIOTECHNOLOGY
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters
- (2013) Amit Garg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Octreotide
- (2013) Mallory M. Chan et al. CHEST
- Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review
- (2013) Algenes Aranha et al. Endocrine Practice
- Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins
- (2013) A. Richter et al. FEBS LETTERS
- Pharmacokinetics of Peptide–Fc Fusion Proteins
- (2013) W.U. Benjamin et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Advances in targeting cell surface signalling molecules for immune modulation
- (2013) Sheng Yao et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody-Based Immunotherapy of Cancer
- (2012) Louis M. Weiner et al. CELL
- A novel peptide (Thx) homing to non-small cell lung cancer identified by ex vivo phage display
- (2012) A. Koivistoinen et al. Clinical & Translational Oncology
- Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
- (2012) P. A. Tang et al. CLINICAL CANCER RESEARCH
- The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
- (2012) R. J. Boohaker et al. CURRENT MEDICINAL CHEMISTRY
- Immunocytokines: a novel class of potent armed antibodies
- (2012) Nadine Pasche et al. DRUG DISCOVERY TODAY
- Pertuzumab
- (2012) Gillian M. Keating DRUGS
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo
- (2012) Ikuhiko Nakase et al. JOURNAL OF CONTROLLED RELEASE
- Targeted drug delivery for cancer therapy: the other side of antibodies
- (2012) Michael A Firer et al. Journal of Hematology & Oncology
- Abstract B237: Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC)
- (2012) P. Woll et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein transduction in human cells is enhanced by cell-penetrating peptides fused with an endosomolytic HA2 sequence
- (2012) Ji-Sing Liou et al. PEPTIDES
- Peptides for cell-selective drug delivery
- (2012) Nina Svensen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Integrin Targeted Delivery of Chemotherapeutics
- (2012) Kai Chen et al. Theranostics
- DARTs take aim at BiTEs
- (2011) C. Rader BLOOD
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
- (2011) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- (2011) M. Steiner et al. CLINICAL CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
- (2011) D. Chen et al. CURRENT CANCER DRUG TARGETS
- DARPins and other repeat protein scaffolds: advances in engineering and applications
- (2011) Ykelien L Boersma et al. CURRENT OPINION IN BIOTECHNOLOGY
- Targeted Radiotherapy with Radiolabeled Somatostatin Analogs
- (2011) Guillaume Nicolas et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling
- (2011) Ykelien L. Boersma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Teaching an Old Scaffold New Tricks: Monobodies Constructed Using Alternative Surfaces of the FN3 Scaffold
- (2011) Akiko Koide et al. JOURNAL OF MOLECULAR BIOLOGY
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
- (2011) M. Grunnet et al. LUNG CANCER
- A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
- (2011) Stuart L. Emanuel et al. mAbs
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
- (2010) Mikkel Østergaard et al. ARTHRITIS AND RHEUMATISM
- Bispecific Antibodies for Cancer Immunotherapy
- (2010) Dafne Müller et al. BIODRUGS
- A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity
- (2010) P. Martin-Killias et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab
- (2010) Bing-Bing Yang et al. CLINICAL PHARMACOKINETICS
- Homing peptides as targeted delivery vehicles
- (2010) Pirjo Laakkonen et al. Integrative Biology
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Approach to the patient after relapse of hairy cell leukemia
- (2010) Robert J. Kreitman et al. LEUKEMIA & LYMPHOMA
- Anti-TNFα domain antibody construct CEP-37247
- (2010) Robert D. Gay et al. mAbs
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- (2010) Gregory L. Moore et al. mAbs
- The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold
- (2010) B. J. Hackel et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231
- (2009) Sonia Aroui et al. CANCER LETTERS
- Engineered therapeutic antibodies with improved effector functions
- (2009) Tsuguo Kubota et al. CANCER SCIENCE
- BiTE: A new class of antibodies that recruit T-cells
- (2009) P.A. Baeuerle et al. DRUGS OF THE FUTURE
- Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors
- (2009) N. Yamamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. JOURNAL OF UROLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- (2009) James A Bonner et al. LANCET ONCOLOGY
- EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
- (2009) J. Winkler et al. MOLECULAR CANCER THERAPEUTICS
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
- (2009) D. Schonfeld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
- (2008) C. S. Tam et al. BLOOD
- The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
- (2008) Sean P Dineen et al. BMC CANCER
- Clinical pharmacokinetics of bevacizumab in patients with solid tumors
- (2008) Jian-Feng Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Functions of Anti-MAGE T-Cells Induced in Melanoma Patients under Different Vaccination Modalities
- (2008) T. Connerotte et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Alternative binding proteins: Anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities
- (2008) Arne Skerra FEBS Journal
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
- (2008) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells
- (2008) Christian Kellner et al. JOURNAL OF IMMUNOTHERAPY
- Picomolar Affinity Fibronectin Domains Engineered Utilizing Loop Length Diversity, Recursive Mutagenesis, and Loop Shuffling
- (2008) Benjamin J. Hackel et al. JOURNAL OF MOLECULAR BIOLOGY
- Cancer Immunotherapy — The Endgame Begins
- (2008) Louis M. Weiner NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters
- (2008) E. A. Dubikovskaya et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More